| 1 Global state: 1a. No clinically significant response (as defined by the original studies) |
4 |
1274 |
Risk Ratio (M-H, Random, 95% CI) |
1.12 [0.93, 1.35] |
| 2 Global state: 1b. No clinically important change (as defined by the original studies) |
4 |
1274 |
Risk Ratio (M-H, Random, 95% CI) |
1.16 [0.99, 1.35] |
| 2.1 short term |
3 |
1007 |
Risk Ratio (M-H, Random, 95% CI) |
1.16 [0.94, 1.44] |
| 2.2 long term |
1 |
267 |
Risk Ratio (M-H, Random, 95% CI) |
1.18 [0.87, 1.60] |
| 3 Leaving the study early |
10 |
|
Risk Ratio (M-H, Random, 95% CI) |
Subtotals only |
| 3.1 any reason |
10 |
2278 |
Risk Ratio (M-H, Random, 95% CI) |
1.06 [0.98, 1.15] |
| 3.2 due to adverse events |
7 |
1851 |
Risk Ratio (M-H, Random, 95% CI) |
1.19 [0.78, 1.80] |
| 3.3 due to inefficacy |
7 |
1851 |
Risk Ratio (M-H, Random, 95% CI) |
1.26 [0.99, 1.61] |
| 4 Mental state: 1a General - no clinically important change - short term (less than 30% PANSS total score reduction) |
2 |
982 |
Risk Ratio (M-H, Random, 95% CI) |
1.11 [0.87, 1.42] |
| 5 Mental state: 1b. General - no clinicallly important change - short term (less than 20% BPRS total score reduction) |
1 |
25 |
Risk Ratio (M-H, Random, 95% CI) |
0.98 [0.63, 1.52] |
| 6 Mental state: 1c. General - average endpoint score (PANSS total score, high=poor) |
9 |
1953 |
Mean Difference (IV, Random, 95% CI) |
3.09 [1.01, 5.16] |
| 6.1 short term |
5 |
1064 |
Mean Difference (IV, Random, 95% CI) |
2.44 [−0.81, 5.69] |
| 6.2 medium term |
2 |
146 |
Mean Difference (IV, Random, 95% CI) |
6.27 [−3.94, 16.48] |
| 6.3 long term |
2 |
743 |
Mean Difference (IV, Random, 95% CI) |
3.11 [0.40, 5.82] |
| 7 Mental state: 1d. General -average endpoint score - short term (BPRS total score, high= poor) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
1.68 [−8.33, 11.69] |
| 8 Mental state: 2a. Positive symptoms - no clinically important change - short term (less than 40% PANSS positive reduction) |
1 |
673 |
Risk Ratio (M-H, Random, 95% CI) |
1.00 [0.90, 1.12] |
| 9 Mental state: 2b. Positive symptoms - average endpoint score - (PANSS positive subscore, high=poor) |
7 |
1264 |
Mean Difference (IV, Random, 95% CI) |
1.82 [1.16, 2.48] |
| 9.1 short term |
4 |
1037 |
Mean Difference (IV, Random, 95% CI) |
2.10 [1.00, 3.19] |
| 9.2 medium term |
2 |
146 |
Mean Difference (IV, Random, 95% CI) |
2.15 [−0.01, 4.31] |
| 9.3 long term |
1 |
81 |
Mean Difference (IV, Random, 95% CI) |
1.30 [−0.13, 2.73] |
| 10 Mental state: 2c. Positive symptoms - average endpoint score - short term (BPRS positive subscore, high=poor) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
1.1 [0.18, 2.02] |
| 11 Mental state: 3a. Negative symptoms - no clinicallly important change - short term (less than 40% PANSS negative reduction) |
1 |
673 |
Risk Ratio (M-H, Random, 95% CI) |
0.98 [0.93, 1.04] |
| 12 Mental state: 3b. Negative symptoms - average endpoint score - (PANSS negative subscore, high=poor) |
7 |
1183 |
Mean Difference (IV, Random, 95% CI) |
−0.35 [−1.95, 1.26] |
| 12.1 short term |
4 |
956 |
Mean Difference (IV, Random, 95% CI) |
−1.46 [−4.11, 1.19] |
| 12.2 medium term |
2 |
146 |
Mean Difference (IV, Random, 95% CI) |
1.30 [−0.75, 3.35] |
| 12.3 long term |
1 |
81 |
Mean Difference (IV, Random, 95% CI) |
0.80 [−0.64, 2.24] |
| 13 Mental state: 3c. Negative symptoms - average endpoint score - (BPRS negative subscore, high=poor) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
0.57 [0.17, 0.97] |
| 14 Quality of life: General- average endpoint score - short term (QLS total score, high=poor) |
1 |
22 |
Mean Difference (IV, Random, 95% CI) |
−0.5 [−13.87, 12.87] |
| 15 Service use: number of participants re-hospitalised |
2 |
877 |
Risk Ratio (M-H, Random, 95% CI) |
1.34 [1.00, 1.79] |
| 15.1 medium term |
1 |
199 |
Risk Ratio (M-H, Random, 95% CI) |
1.3 [0.71, 2.38] |
| 15.2 long term |
1 |
678 |
Risk Ratio (M-H, Random, 95% CI) |
1.35 [0.97, 1.88] |
| 16 Adverse effects: 1. General - at least one adverse effect |
8 |
2226 |
Risk Ratio (M-H, Random, 95% CI) |
1.04 [0.93, 1.17] |
| 17 Adverse effects: 2. Death |
5 |
3066 |
Risk Ratio (M-H, Random, 95% CI) |
0.73 [0.17, 3.09] |
| 17.1 natural causes |
2 |
982 |
Risk Ratio (M-H, Random, 95% CI) |
Not estimable |
| 17.2 suicide attempt |
2 |
945 |
Risk Ratio (M-H, Random, 95% CI) |
0.43 [0.06, 2.95] |
| 17.3 suicide |
3 |
1139 |
Risk Ratio (M-H, Random, 95% CI) |
1.41 [0.11, 18.32] |
| 18 Adverse effects: 3a. Cardiac effects - QTc prolongation |
2 |
1351 |
Risk Ratio (M-H, Random, 95% CI) |
0.87 [0.29, 2.55] |
| 19 Adverse effects: 3b. Cardiac effects - QTc abnormalities -change from baseline in ms |
3 |
940 |
Mean Difference (IV, Random, 95% CI) |
2.21 [−5.05, 9.48] |
| 20 Adverse effects: 4. Central nervous system - sedation |
8 |
2226 |
Risk Ratio (M-H, Fixed, 95% CI) |
1.21 [1.06, 1.38] |
| 21 Adverse effects: 5a. Extrapyramidal effects |
8 |
|
Risk Ratio (M-H, Random, 95% CI) |
Subtotals only |
| 21.1 akathisia |
6 |
2170 |
Risk Ratio (M-H, Random, 95% CI) |
0.62 [0.34, 1.13] |
| 21.2 akinesia |
1 |
267 |
Risk Ratio (M-H, Random, 95% CI) |
0.91 [0.61, 1.37] |
| 21.3 dystonia |
1 |
673 |
Risk Ratio (M-H, Random, 95% CI) |
0.06 [0.01, 0.41] |
| 21.4 extrapyramidal symptoms |
2 |
872 |
Risk Ratio (M-H, Random, 95% CI) |
0.59 [0.43, 0.81] |
| 21.5 parkinsonism |
2 |
717 |
Risk Ratio (M-H, Random, 95% CI) |
0.06 [0.00, 0.96] |
| 21.6 rigor |
1 |
309 |
Risk Ratio (M-H, Random, 95% CI) |
0.45 [0.16, 1.25] |
| 21.7 use of antiparkinson medication |
6 |
1715 |
Risk Ratio (M-H, Random, 95% CI) |
0.50 [0.30, 0.86] |
| 22 Adverse effects: 5b. Extrapyramidal effects - scale measured |
5 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 22.1 abnormal involuntary movement: AIMS (high=poor) |
2 |
958 |
Mean Difference (IV, Random, 95% CI) |
−0.34 [−0.76, 0.08] |
| 22.2 akathisia: Barnes Akathisia Scale (high=poor) |
2 |
700 |
Mean Difference (IV, Random, 95% CI) |
−0.73 [−2.00, 0.54] |
| 22.3 extrapyramidal symptoms: Simpson-Angus Scale (high=poor) |
5 |
1077 |
Mean Difference (IV, Random, 95% CI) |
−0.59 [−1.16, −0.02] |
| 23 Adverse effects: 6. Haematological: important decline in white blood cells |
1 |
673 |
Risk Ratio (M-H, Random, 95% CI) |
2.97 [0.12, 72.73] |
| 24 Adverse effects: 7a. Prolactin associated side effects |
6 |
|
Risk Ratio (M-H, Random, 95% CI) |
Subtotals only |
| 24.1 amenorrhea |
4 |
359 |
Risk Ratio (M-H, Random, 95% CI) |
0.47 [0.28, 0.79] |
| 24.2 dysmenorrhea |
1 |
163 |
Risk Ratio (M-H, Random, 95% CI) |
0.45 [0.08, 2.38] |
| 24.3 galactorrhea |
5 |
1188 |
Risk Ratio (M-H, Random, 95% CI) |
0.37 [0.16, 0.85] |
| 24.4 gynecomastia |
1 |
267 |
Risk Ratio (M-H, Random, 95% CI) |
0.23 [0.07, 0.79] |
| 24.5 sexual dysfunction |
6 |
2157 |
Risk Ratio (M-H, Random, 95% CI) |
0.70 [0.48, 1.01] |
| 25 Adverse effects: 7b. Prolactin -change from baseline in mg/dl |
6 |
1731 |
Mean Difference (IV, Random, 95% CI) |
−35.28 [−44.36, −26. 19] |
| 26 Adverse effects: 8a. Metabolic - cholesterol - significant cholesterol increase |
2 |
940 |
Risk Ratio (M-H, Random, 95% CI) |
1.27 [0.72, 2.24] |
| 27 Adverse effects: 8b. Metabolic - cholesterol - change from baseline in mg/dl |
5 |
1433 |
Mean Difference (IV, Random, 95% CI) |
8.61 [4.66, 12.56] |
| 28 Adverse effects: 8c. Metabolic - glucose - abnormally high fasting glucose value |
2 |
940 |
Risk Ratio (M-H, Random, 95% CI) |
1.39 [0.56, 3.45] |
| 29 Adverse effects: 8d. Metabolic -glucose - change from baseline in mg/dl |
5 |
1436 |
Mean Difference (IV, Random, 95% CI) |
−0.04 [−2.92, 2.83] |
| 30 Adverse effects: 8e. Metabolic -weight gain of 7% or more of total body weight |
7 |
1942 |
Risk Ratio (M-H, Random, 95% CI) |
0.97 [0.82, 1.14] |
| 31 Adverse effects: 8f. Metabolic - weight gain - change from baseline in kg |
7 |
1446 |
Mean Difference (IV, Random, 95% CI) |
0.71 [−1.04, 2.47] |
